首頁 > 市場調查報告書 > 製藥

疫苗感染疾病

市場調查報告書

商品編碼

1547935

全球腦膜炎雙球菌疫苗市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Meningococcal Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球腦膜炎雙球菌疫苗市場需求預計將從 2023 年的 55.7 億美元達到近 102.8 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.05%。

腦膜炎雙球菌疫苗有助於預防腦膜炎雙球菌疾病。腦膜炎球菌疾病是由腦膜炎奈瑟菌引起的。疫苗含有抗原物質，可以增強人體的免疫系統並使其產生抗體，然後這些抗體透過攻擊和殺死細菌來保護身體。疫苗透過注射到肌肉或皮下注射。腦膜炎雙球菌疫苗有三種類型：多醣體疫苗、結合疫苗和蛋白質疫苗。

市場動態

流行性腦膜炎發病率的不斷上升正在推動市場的成長。腦膜炎球菌疾病可能是致命的，全世界所有國家都觀察到這種疾病，但這種疾病的負擔最重的是撒哈拉以南非洲地區，從西部的塞內加爾到東部的埃塞俄比亞。的浪潮成長歸因於新型冠狀病毒肺炎 (COVID-19)，這是一種新興的、快速發展的情況。進行各種臨床試驗以確定結果。多種藥物和疫苗被確定為根除 COVID-19 的候選藥物和疫苗。 ChAdOx1 nCoV-19 腦膜炎雙球菌疫苗就是其中之一。這種疫苗的作用是啟動免疫系統識別和攻擊冠狀病毒，刺激 T 細胞反應，並且在動物和早期人體測試中似乎是安全的，這給冠狀病毒版本和市場成長帶來了信心。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球腦膜炎雙球菌疫苗市場的各個細分市場進行了包容性評估。腦膜炎球菌疫苗產業的成長和趨勢為本研究提供了整體方法。

市場區隔

腦膜炎球菌疫苗市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按類型

二價
四價
其他

按品牌

梅納克特拉
門維奧
尼門里克斯
特魯門巴
貝克塞羅
其他

按年齡段

嬰兒（0 至 2 歲）
兒童及成人（2歲以上）

依血清型分類

A血清型
B血清型
C血清型
血清型 W-135
Y血清型

按銷售管道

私人的
民眾

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲腦膜炎球菌疫苗市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。腦膜炎球菌疫苗市場的主要參與者包括輝瑞公司、賽諾菲公司、印度血清研究所有限公司、葛蘭素史克公司、默克公司、沃瓦克斯生物技術有限公司。整體視圖其中包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按類型分類的市場吸引力分析
- 按品牌分類的市場吸引力分析
- 按年齡層別分類的市場吸引力分析
- 依血清型進行市場吸引力分析
- 按銷售管道分類的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球腦膜炎雙球菌疫苗市場分析：按類型

按類型概述
歷史和預測數據
按類型分析
二價
四價
其他

第 6 章：全球腦膜炎雙球菌疫苗市場分析：按品牌

按品牌概覽
歷史和預測數據
按品牌分析
梅納克特拉
門維奧
尼門里克斯
特魯門巴
貝克塞羅
其他

第 7 章：全球腦膜炎雙球菌疫苗市場分析：依年齡層別分類

依年齡層別概覽
歷史和預測數據
按年齡層分析
嬰兒（0 至 2 歲）
兒童及成人（2歲以上）

第 8 章：全球腦膜炎雙球菌疫苗市場分析：依血清型分類

按血清型概述
歷史和預測數據
依血清型分析
A血清型
B血清型
C血清型
血清型 W-135
Y血清型

第 9 章：全球腦膜炎雙球菌疫苗市場分析：按銷售管道

銷售通路概覽
歷史和預測數據
按銷售管道分析
私人的
民眾

第 10 章：全球腦膜炎雙球菌疫苗市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 11 章：腦膜炎雙球菌疫苗公司的競爭格局

腦膜炎雙球菌疫苗市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 12 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

Serum Institute Of India Ltd.

公司概況
公司收入
產品
最新動態

GSK Plc.

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

Walvax Biotechnology Co. Ltd

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11212373

The global demand for Meningococcal Vaccine Market is presumed to reach the market size of nearly USD 10.28 Billion by 2032 from USD 5.57 Billion in 2023 with a CAGR of 7.05% under the study period 2024-2032.

Meningococcal vaccine helps prevent meningococcal disease. The meningococcal disease is caused by Neisseria meningitides bacteria. The vaccines contain antigens substances that boost the body's immune system and cause it to make antibodies, these antibodies then protect the body by attacking and killing the bacteria. The vaccine is given either by injection into a muscle or just under the skin. There are three types of meningococcal vaccines available: Polysaccharide vaccines, conjugate vaccines, and protein based vaccine.

MARKET DYNAMICS

Growing incidence of meningococcal meningitis is driving the growth of market. Meningococcal disease is potentially fatal, observed worldwide with reportable condition in all states, but the highest burden of the disease is in the sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east.Market is predicted to experience new waves in the growth owing to the COVID-19, an emerging an rapidly evolving situation.Scientist across the world are focused on discovering vaccine for coronavirus. Various clinical trials are executed to determine the results. Number of drugs and vaccine is identified as candidate to eradicate COVID-19. ChAdOx1 nCoV-19, vaccine against meningococcal disease is among the one. This vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response and has appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version and market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Meningococcal Vaccine. The growth and trends of Meningococcal Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Meningococcal Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Bivalent
Quadrivalent
Others

By Brand

Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others

By Age Group

Infants (0 to 2 years)
Children and Adults (2 years & above)

By Serotype

Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y

By Sales Channel

Private
Public

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Meningococcal Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Meningococcal Vaccine market include Pfizer Inc., Sanofi, Serum Institute Of India Ltd., GSK Plc., Merck & Co. Inc., Walvax Biotechnology Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MENINGOCOCCAL VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Brand
- 3.7.3 Market Attractiveness Analysis By Age Group
- 3.7.4 Market Attractiveness Analysis By Serotype
- 3.7.5 Market Attractiveness Analysis By Sales Channel
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Bivalent Historic and Forecast Sales By Regions
5.5. Quadrivalent Historic and Forecast Sales By Regions
5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY BRAND

6.1. Overview By Brand
6.2. Historical and Forecast Data
6.3. Analysis By Brand
6.4. Menactra Historic and Forecast Sales By Regions
6.5. Menveo Historic and Forecast Sales By Regions
6.6. Nimenrix Historic and Forecast Sales By Regions
6.7. Trumenba Historic and Forecast Sales By Regions
6.8. Bexsero Historic and Forecast Sales By Regions
6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY AGE GROUP

7.1. Overview By Age Group
7.2. Historical and Forecast Data
7.3. Analysis By Age Group
7.4. Infants (0 to 2 years) Historic and Forecast Sales By Regions
7.5. Children and Adults (2 years & above) Historic and Forecast Sales By Regions

8. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SEROTYPE

8.1. Overview By Serotype
8.2. Historical and Forecast Data
8.3. Analysis By Serotype
8.4. Serotype A Historic and Forecast Sales By Regions
8.5. Serotype B Historic and Forecast Sales By Regions
8.6. Serotype C Historic and Forecast Sales By Regions
8.7. Serotype W-135 Historic and Forecast Sales By Regions
8.8. Serotype Y Historic and Forecast Sales By Regions

9. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SALES CHANNEL

9.1. Overview By Sales Channel
9.2. Historical and Forecast Data
9.3. Analysis By Sales Channel
9.4. Private Historic and Forecast Sales By Regions
9.5. Public Historic and Forecast Sales By Regions

10. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE MENINGOCOCCAL VACCINE COMPANIES

11.1. Meningococcal Vaccine Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF MENINGOCOCCAL VACCINE INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Pfizer Inc.
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Sanofi
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. Serum Institute Of India Ltd.
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. GSK Plc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. Merck & Co. Inc.
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Walvax Biotechnology Co. Ltd
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments